Contineum Therapeutics, Inc. Share Price
Equities
CTNM
US21217B1008
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.48 USD | -2.09% | +4.45% | 0.00% |
04-30 | Morgan Stanley Starts Contineum Therapeutics With Overweight Rating | MT |
04-30 | Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target | MT |
Sales 2024 * | - | Sales 2025 * | 15M 1.19B | Capitalization | 389M 30.98B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | 99.6M 7.93B | Net cash position 2025 * | 53.37M 4.25B | EV / Sales 2025 * | 22.4 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 31 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.81% |
1 day | -2.09% | ||
1 week | +4.45% | ||
Current month | -0.77% | ||
1 month | -0.13% |
Date | Price | Change | Volume |
---|---|---|---|
13/05/24 | 15.48 | -2.09% | 27,651 |
10/05/24 | 15.81 | -1.31% | 74,968 |
09/05/24 | 16.02 | +2.10% | 147,228 |
08/05/24 | 15.69 | +5.94% | 114,226 |
07/05/24 | 14.81 | -0.07% | 77,411 |
Delayed Quote Nasdaq, May 13, 2024 at 09:00 pm
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
0.00% | 389M | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+45.09% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- CTNM Stock